Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/100 microgram(s) - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s) - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500 microgram(s) - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - salmeterol xinafoate, fluticasone propionate - powder for inhalation - 50/500 microgram - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics, inhalants; adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics. - lifsar pulmojet is indicated for the symptomatic treatment of adults with chronic obstructive pulmonary disease (copd) with a fev1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations and who have significant symptoms despite regular bronchodilator therapy.